Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41160742.
- Also identified by DOI 10.1146/annurev-med-043024-011141.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) agonists were originally developed as treatments for diabetes and subsequently evolved into weight management medications. These drugs have recently been shown to demonstrate remarkable efficacy in cardiovascular disease, kidney disease, and heart failure with preserved ejection fraction (HFpEF). In this review, we focus on the cardiovascular protective effects of GLP-1R agonists identified from basic studies and outcome trials, including a brief description of those forthcoming soon.
Medical subject headings
- Glucagon-Like Peptide-1 Receptor Agonists
- Cardiovascular Diseases
- Hypoglycemic Agents
- Diabetes Mellitus, Type 2